United Therapeutics (UTHR) Shares Outstanding (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Shares Outstanding (Entity) data on file, last reported at $43.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Entity) fell 3.12% year-over-year to $43.5 million; the trailing twelve-month figure through Mar 2026 stood at $43.5 million (down 3.12% YoY), and the FY2025 full-year result was $44.3 million, down 1.99% from the prior year.
• Shares Outstanding (Entity) declined to $43.5 million in Q1 2026, from $44.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $47.0 million in Q1 2024 to a low of $43.5 million in Q1 2026.
• A 5-year average of $45.4 million and a median of $45.2 million in 2022 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) increased 3.3% in 2023 and retreated 5.33% in 2024, its largest moves.
• Tracing UTHR's Shares Outstanding (Entity) over 5 years: stood at $45.5 million in 2022, then gained by 2.86% to $46.8 million in 2023, then slipped by 3.42% to $45.2 million in 2024, then decreased by 1.99% to $44.3 million in 2025, then slipped by 1.81% to $43.5 million in 2026.
• Business Quant data shows UTHR's Shares Outstanding (Entity) at $43.5 million in Q1 2026, $44.3 million in Q4 2025, and $43.8 million in Q3 2025.